{
    "nctId": "NCT00092183",
    "briefTitle": "An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)",
    "officialTitle": "A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Nausea, Vomiting, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 866,
    "primaryOutcomeMeasure": "Emesis and use of rescue medication",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.\n\nExclusion Criteria:\n\n* Patient has a central nervous system malignancy.\n* Patient will receive radiation to the abdomen or pelvis.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}